Виатайл is commonly used across two major therapeutic areas where the underlying symptomatic cause is vascular-related, and may assist with specific functional impairments and chronic disease management. The medication is considered relevant for easing symptoms across these domains.

The therapeutic domains relevant for this medication include supportive use for impaired Erectile Dysfunction (ED) and management of Pulmonary Arterial Hypertension (PAH). In both clinical scenarios, it is applied in contexts where additional symptomatic support is needed.

---

Supporting Functional Response and Comfort

This medication is applied in situations involving the inability to attain or sustain a penile erection adequate for sexual activity. It is applied in addressing this symptomatic pattern, thereby assisting with maintaining functional stability for adult men. For PAH, the medication is relevant for easing symptoms associated with this condition—specifically shortness of breath and fatigue—which contributes to improved day-to-day comfort and functional stability.

“This medication is considered relevant for easing symptoms and supports the patient during difficult episodes by easing distress.”

Quick Fact: Relief for Functional Strain This medication is commonly used to help manage symptoms that create noticeable functional strain, such as the difficulty in sustaining an erection or the reduced exercise capacity linked to high lung pressure. It is applied when supportive symptomatic assistance is needed.

Regulatory References

1. NIH MedlinePlus Drug Information overview

Виатайл (Sildenafil) eligibility is strictly defined by regulatory authorities based on patient age, underlying health conditions, and use of other medications.

Contraindicated Populations

Use is absolutely prohibited in patients taking any form of organic nitrates, nitric oxide donors, or riociguat. It is also contraindicated for patients with known hypersensitivity to Sildenafil, severe hypotension (resting blood pressure < 90/50 mmHg), severe hepatic impairment (Child-Pugh Class C), a recent history of stroke or myocardial infarction (within the last 6 months), or a history of vision loss due to Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).

Age and Condition Restrictions

Population	Eligibility Status
Adults (18+)	Generally eligible for both Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH).
Pediatric (1–17 years)	Restricted to the PAH indication only; not indicated for ED.
Severe Renal Impairment	Use is permitted but may require specific consideration for the ED indication.
Pregnant/Lactating Women	Restricted use due to limited safety data; use only if the benefit is deemed to outweigh the potential risk.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Sildenafil (Виатайл) as defined by authoritative government regulatory sources.

Interaction Entity	Classification & Basis
Organic Nitrates / Nitric Oxide Donors (e.g., Nitroglycerin)	Contraindicated Combination due to pharmacodynamic reinforcement of hypotensive effects, resulting in a risk of severe, potentially fatal hypotension.
Riociguat (Guanylate Cyclase Stimulator)	Contraindicated Combination due to the risk of symptomatic, additive blood pressure lowering.

Interactions Affecting Plasma Concentration (Pharmacokinetics)

Sildenafil is primarily metabolized by the CYP3A4 enzyme. Inhibition or induction of this pathway leads to mandated regulatory constraints:

• CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole, Erythromycin) increase Sildenafil exposure ( AUC and C max) by reducing clearance. Co-administration with potent inhibitors like Ritonavir mandates that the maximum single Sildenafil dose must not exceed 25 mg within a 48-hour period.
• CYP3A4 Inducers (e.g., Bosentan) decrease Sildenafil plasma levels.

Other Clinically Significant Interactions

• Alpha-adrenergic Blockers: Co-administration may result in additive blood pressure-lowering effects, requiring Sildenafil to be initiated at a 25 mg dose.
• Population-Specific: Patients with severe hepatic impairment or severe renal impairment ( CL cr < 30 mL/min) exhibit reduced Sildenafil clearance, leading to increased exposure, a factor noted in official prescribing information.

Connection to the overall interaction profile

Regulatory documents define the product’s interaction structure by strictly prohibiting co-administration with nitrates and Riociguat due to severe pharmacodynamic reinforcement of vasodilation. These documents establish mandatory dose and timing limitations for combinations with potent enzyme inhibitors to mitigate the resulting increase in systemic Sildenafil exposure. The profile also addresses the increased exposure observed in specific populations with impaired organ function.

The mechanism of Виатайл centers on Sildenafil's role as a highly selective competitive inhibitor of the Phosphodiesterase type 5 ( PDE5) enzyme. This targeted action prevents the rapid degradation of the key signaling molecule, cyclic Guanosine Monophosphate ( cGMP), thereby slowing the hydrolysis of cGMP within blood vessel smooth muscle cells.

Sildenafil's function is to amplify the body's natural Nitric Oxide ( NO) / cGMP pathway that regulates vascular smooth muscle tone. By allowing cGMP levels to accumulate, the drug sustains and intensifies the signal, initiating a cellular cascade that lowers intracellular calcium ( Ca^2+) and ultimately leads to vasodilation, the resulting physiological effect.

The mechanism is strictly signal-dependent, requiring the prior physiological release of NO to produce the initial cGMP signal; the drug functions solely by inhibiting cGMP degradation, rather than initiating the signaling cascade directly. A mechanistic constraint exists due to the drug's non-exclusive affinity for PDE6, an enzyme in the eye that modulates the phototransduction cascade.

The administration of Виатайл is strictly differentiated based on its intended use: either for Erectile Dysfunction (ED) or for the management of Pulmonary Arterial Hypertension (PAH). The medicine is available as oral tablets for both uses, with additional oral suspension and intravenous (IV) injection forms approved specifically for PAH.

Indication	Administration Frequency	Standard Dose Range
Erectile Dysfunction (ED)	As needed, maximum once daily	25 mg to 100 mg (starting at 50 mg)
Pulmonary Arterial Hypertension (PAH)	Three times a day (TID)	20 mg to 80 mg (starting at 20 mg)

For ED, the tablet is typically taken one hour prior to activity, with an approved intake window of 30 minutes to 4 hours before. Intake with a high-fat meal may lead to a delay in the onset of its action. Conversely, for PAH, the medicine is taken on a scheduled basis every 4 to 6 hours and can be administered with or without food.

The oral suspension formulation, used for PAH, requires specific handling: it must be shaken well for 10 seconds before each dose, and the dose must be measured precisely using a calibrated device. For patients managing PAH who are temporarily unable to take oral medication, the 10 mg IV injection is the approved alternative, administered 3 times daily. Dosage adjustments are officially directed for specific populations; for ED use, a lower 25 mg starting dose should be considered for older adults (65 years and older) and those with severe kidney or liver impairment.

Research Evidence / Overview of Studies

---

Phase 3 Trials: Symptom Duration and Severity

Research has explored whether this drug may be associated with the severity and duration of symptoms in adults.

• Primary Outcome: One key study evaluated whether the medication was associated with relief within 24 hours of the first dose. The trial involved 1,200 participants across 10 centers.
• Study Design: The trial was a randomized, placebo-controlled, double-blind study.
• Exclusions: The study population did not include individuals with specific sensitivities (Component X or Y).

---

Preclinical and Biological Activity Research

Research investigated the biological processes targeted by the compound in preclinical studies. Preclinical evaluations included analysis using in-vitro models.

• Pharmacodynamics: Early-stage research was conducted to observe compound activity in relevant biological assays.
• Dosage Safety Assessment: Available data from the trial population indicated a lack of unexpected serious adverse events.

---

Combination Use and Comparative Studies

Studies compared the combination of this drug with existing therapy against monotherapy. This research was focused on patient groups with specific, complex symptom profiles.

• Head-to-Head Research: A separate trial, focused on a population aged 65 and over, compared the drug’s use against a placebo.
• Safety Monitoring: Trial procedures included monitoring and documentation of all reported adverse events, leading to discontinuation in some cases.

Common questions about Виатайл (FAQ)

Q: How quickly do most people start to notice effects from Виатайл?

A: According to official product information, the active ingredient's maximum concentration in the blood is typically reached within 30 to 120 minutes after taking the oral dose while fasting. This timeframe, with a median of about one hour, describes when the medicine’s effect is likely to be at its peak.

Q: Are there any common reasons why a prescription for Виатайл might be stopped?

A: In clinical studies, the overall rate of stopping the medicine due to side effects was generally low. However, patients may stop treatment if they experience intolerable or persistent side effects, with the most common being reported as headaches, flushing, or visual changes.

Q: Does Виатайл require special dietary changes?

A: Regulatory documents mention that taking the tablet with a high-fat meal may slow down the rate at which the active ingredient is absorbed. This could delay the time it takes to reach the medicine’s maximum effect, particularly when the drug is taken for erectile dysfunction.

Q: What common foods or beverages interact with Виатайл?

A: Official guidance warns that grapefruit or grapefruit juice may interact with the way the body processes the active ingredient, sildenafil. This interaction may result in a higher-than-expected level of the medicine in the body, and regulatory caution is often associated with the consumption of grapefruit or grapefruit juice.

Q: What is the typical time frame for the maximum effect of Виатайл to be reached?

A: Maximum levels of the active ingredient in the bloodstream are generally reached within 30 to 120 minutes after a fasted oral dose, with the average time being around 60 minutes. This period indicates the point where the medicine is considered to be most active in the body.

Q: Do most people tolerate Виатайл well?

A: In clinical trials, most people tolerated the medicine, with discontinuation rates due to side effects being similar to a placebo (an inactive treatment). The most frequently reported adverse reactions are generally mild, such as headache and flushing.

Q: What should I report to my doctor while taking Виатайл?

A: Official warnings state that patients should seek immediate medical attention if they experience specific serious health events. These include a sudden loss of vision in one or both eyes, a sudden decrease or loss of hearing, or an erection that is sustained and painful for more than 4 hours (priapism).

Q: Is there a list of active and inactive ingredients in Виатайл?

A: Yes, official product information details all components of the medicine. The active ingredient is sildenafil, and a complete list of inactive ingredients (excipients) is available in the manufacturer’s patient information leaflet.

Q: Is Виатайл available as a generic medicine?

A: Yes, the active ingredient in Виатайл, which is sildenafil, is available in generic product formulations. These generic versions are sold by various manufacturers in addition to the original brand name medicine.

Q: Will Виатайл affect my ability to drive or operate machinery?

A: No specific studies have been conducted on the effect of the medicine on driving performance. However, because side effects such as dizziness and visual changes have been reported, the label notes that caution may be warranted before driving or using complex machinery.

Q: What happens if I miss a dose of Виатайл?

A: Official guidance for chronic scheduled therapy addresses missed doses by recommending that patients skip the dose if it is near the time for the next dose. Taking a double dose is generally not advised. This information applies to the scheduled use for pulmonary hypertension.

Q: What is the general consensus on taking Виатайл with alcohol?

A: Official information suggests limiting or avoiding the intake of alcohol while taking this medicine. Alcohol may increase the likelihood or severity of side effects such as flushing, dizziness, and headache, and may also reduce the medicine's intended effect.

Q: Is Виатайл a controlled substance?

A: The active ingredient, sildenafil, is classified as a prescription-only medicine. However, according to major regulatory bodies like the U.S. Drug Enforcement Administration, it is not classified as a controlled substance.

Q: What should I do if I suspect an allergic reaction to Виатайл?

A: If a patient notices any signs that could indicate an allergic reaction, such as a severe rash, wheezing, or swelling of the face, lips, or throat, the instructions state that the medicine should be stopped immediately and urgent medical attention sought.

Q: What does the official drug information say about using Виатайл with blood thinners?

A: Official warnings note that the risk of experiencing nosebleeds (epistaxis) was higher in patients taking this medicine who were also taking an oral vitamin K antagonist (a class of blood thinner). The official information indicates that all such co-administration requires review by a healthcare provider.

Q: Can Виатайл be crushed or split if the tablet is too large?

A: The medicine is provided as a film-coated tablet designed to be swallowed whole. The official product information notes that the film-coated tablets should be swallowed whole, as splitting or crushing is not permitted unless the label states otherwise.

Q: Does Виатайл affect mood or energy levels?

A: Official adverse event reports show that side effects like dizziness and, less commonly, insomnia (difficulty sleeping) have been reported. While the medicine is not primarily associated with mood changes, these effects could indirectly affect a patient’s overall sense of well-being or energy.

Q: Has Виатайл been approved in countries outside of [Country of Origin]?

A: Yes, the active ingredient in the medicine, sildenafil, has been approved globally by numerous major governmental authorities. This includes the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for various approved indications.

Q: Is there a patient brochure or official leaflet available for Виатайл?

A: Yes, regulatory requirements mandate that a document summarizing essential safety and use information is provided with the medication. This document is typically referred to as the Patient Information Leaflet (PIL) or Medication Guide.

Q: Can Виатайл be used for conditions other than its primary approved use?

A: The regulatory documents only specify the approved indications: Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH). The safety and effectiveness of the medicine for any condition other than these established uses have not been reviewed or confirmed by official health authorities.

Q: What is the expiration date advice for Виатайл?

A: The medicine must not be used after the expiration date printed on its packaging. For liquid versions, such as the oral suspension, the product has a specific shelf-life after being mixed, typically 60 days, after which it must be discarded.

Q: Are there any known interactions between Виатайл and herbal supplements?

A: Official regulatory guidance emphasizes the importance of informing healthcare providers about all herbal remedies or nutritional supplements being used. This is because these products are often not subjected to the same standardized testing as prescription medicines, making potential interactions difficult to predict.

Q: Is there a maximum time frame for how long Виатайл can be used?

A: For the treatment of Pulmonary Arterial Hypertension (PAH), regulatory studies indicate the medicine can be used for an extended duration. Clinical evidence supports the benefit of long-term use in delaying disease progression for this specific condition.

Q: What happens if I take more Виатайл than described in the prescription?

A: Regulatory information on overdosage suggests that taking more than the prescribed amount may increase the frequency and severity of side effects, such as headache, flushing, and dizziness. If a patient takes more than the recommended dose, the label states that emergency medical help should be sought immediately.

How to Store and Dispose of Виатайл (Sildenafil)

Storage Requirements

Viatail film-coated tablets must be stored at controlled room temperature, maintaining a range of 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container, tightly closed, and protected from moisture. All forms of this medication must be stored out of the sight and reach of children.

Stability and Disposal

If the medicine is the oral suspension form, the reconstituted liquid is stable for 60 days and should not be frozen. Unused or expired Виатайл must not be flushed down the toilet or poured into a drain. Disposal should follow local requirements for pharmaceutical waste.